Literature DB >> 3875392

Monocyte and lymphocyte interaction in patients with advanced cancer. Evidence for deficient IL-1 production.

L B Santos, F T Yamada, M A Scheinberg.   

Abstract

Patients with advanced neoplasms have a variety of immunologic abnormalities, including the impaired responsiveness of peripheral blood lymphocytes to mitogen and alloantigen. In the current study it was observed that cancer patients have increased monocyte suppressor cell activity that is mediated by prostaglandins and contributes to the depressed proliferative response of the patients' T-cells. This monocyte suppression, however, is not the major cause of the depressed proliferative response. The study also demonstrated that levels of interleukin 1 (IL-1) produced by lypopolysacharide-activated monocytes from cancer patients are significantly lower than they are in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875392     DOI: 10.1002/1097-0142(19851001)56:7<1553::aid-cncr2820560715>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Clinical implications and characteristics of factor forkhead box protein 3 in gastric cancer.

Authors:  Changli Jiang; Weihua Wang; Wei Yan; Yuhai Zhang; Jiangtao Yang; Song Zhang; Cun Zhang; Wei Zhang; Wei Han; Junzhi Wang; Ying-Qi Zhang
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

2.  Decreased interleukin generation in patients with cancer of the digestive system. A correlation between interleukin 1 and interleukin 2 production.

Authors:  Y Haga; K Sakamoto; Y Yokoyama; M Akagi
Journal:  Jpn J Surg       Date:  1988-09

3.  Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas.

Authors:  U Elsässer-Beile; S von Kleist; R Fischer; M Martin; U Wetterauer; H Gallati; J S Mönting
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Cytokine production in whole blood cell cultures of patients undergoing therapy with biological response modifiers or 5-fluorouracil.

Authors:  U Elsässer-Beile; S von Kleist; A Lindenthal; R Birken; H Gallati; J S Mönting
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

5.  Reduced in vitro erythroid progenitor cell growth in bronchial cancer.

Authors:  G S Masters; P Baines; R Bailey-Wood; T Gorvett; T Littlewood; P Bentley; H Parry-Jones; A Jacobs
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

6.  Interleukin-1 production by immunologically hyporeactive tumour-bearing mice.

Authors:  V Holán; M Lipoldová
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

7.  Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages.

Authors:  U Elsässer-Beile; S von Kleist; W Sauther; H Gallati; J S Mönting
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.